Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health

Kanvas makes the microbiome druggable—and the implications are massive

Kanvas looks amazing! They’re systematically deciphering microbiomes and developing clinical-stage interventions to improve patient outcomes in oncology and beyond. Very impressive! I’m also especially interested in their approach to maternal envi­ron­mental enteric dysfunction (EED), which apparently affects 150M people!

Ever since the genomics revolution revealed how reliant the human organism is on its microscopic microbial cohabitants, the microbiome has been medicine’s most elusive frontier, promising better health if only we could untangle the trillions of interactions that influence nearly every facet of our physiology. But until now, effective medicines that harness the microbiome have been rare. Because of the diversity of microbial species and the complexity of host-to-microbe interactions, as well as the lack of a reliable, easily manufactured drug modality (the package that delivers a medicine’s therapeutic effect), the microbiome has been hard to treat, despite its importance to functions like immune response. Microbiome science has disappointed patients, doctors, founders, and investors.

That’s why DCVC is so excited about the cascade of recent developments at Kanvas Biosciences, which is moving the field beyond descriptive profiling of the microbiome to translating comprehensive biochemical insights into clinically useful products. In the past few weeks, the Princeton-based spatial biology company has kicked off a Phase 1 clinical trial for its first drug candidate, secured significant new backing from the Gates Foundation (closing a $48 million Series A financing, bringing Kanvas’s total funding to $78 million), and bolstered its scientific leadership by adding one of the most respected names in bioengineering to its board.

Clinical milestone

The most significant milestone in Kanvas’s evolution is the dosing of the first patients in a Phase I clinical trial for KAN-4. This live biotherapeutic product (LBP), resembling an ordinary pill, treats the colitis that many cancer patients develop after receiving immune checkpoint inhibitors (ICIs), allowing them to remain on the life-saving therapy longer.

The next phase of human evolution is already underway

That is one of the stranger truths about human evolution. Some of the traits helping people survive now are not purely modern at all. They are remnants of older branches of humanity, carried forward because they still work.

Evolution needs variation, inheritance, and reproduction. Those conditions have not disappeared.

Long-term health studies that follow multiple generations indicate that natural selection is still acting in modern populations. Certain traits are associated with having more children, and over time those traits become more common. Patterns in the data point toward earlier childbirth and later menopause, which together extend the reproductive window. Other trends suggest shifts in metabolism, including lower cholesterol and blood pressure.

FDA Approves Novel Weekly Basal Insulin for T2D

The FDA has approved once-weekly insulin icodec-abae (Awiqli; Novo Nordisk) for use in adults with type 2 diabetes (T2D), with a current projected launch in the second half of 20,261 for the 700-units/mL dose. This novel treatment option is a first-in-its-class therapeutic, freeing patients living with T2D from their strict schedule of daily basal insulin injections and reducing total injections from 7 to 1 for each 7-day period.

Its indication is as an adjunct to diet and exercise for improved glycemic control, as well as for patients also taking mealtime insulin or another common oral antidiabetic agent and/or a glucagon-like peptide-1 receptor agonist. A prescription is required, and administration is with or without food via a prefilled FlexTouch device on the same day each week.

Data from 4 of the trials in the phase 3a ONWARDS program and 2,680 adult patients with uncontrolled T2D support this approval; their primary end point of interest was reduction in hemoglobin A1c. Overall, the ONWARDS program encompasses 6 phase 3a trials and more than 4,000 adults with type 1 diabetes (T1D) or T2D.

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries.

Older people with HIV are especially vulnerable to influenza, yet this group remains understudied

https://doi.org/10.1172/jci.insight.199232 Here, Savita G. Pahwa & team demonstrate high-dose vaccination for influenza strengthens immunity in older adults with HIV after prior standard dosing, but not all strain-specific weaknesses were overcome.

1Department of Microbiology and Immunology.

2Division of Biostatistics, Department of Public Health Sciences; and.

3Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Zuckerberg Trying to Simulate Human Biology at the Cellular Level

Mark Zuckerberg is following a path paved by fellow billionaires Bill Gates and Warren Buffet: laundering his untold billions through a health research prestige project.

Called the Chan Zuckerberg Biohub — his wife Priscilla Chan, a pediatrician, is also involved — the foundation’s stated long-term mission is to “cure and prevent all disease through AI-powered biology, frontier research, and state-of-the-art technology.”

True to those enormous goals, the Biohub recently announced a $500 million investment into AI models of human cells, specifically, in order to “accelerate the cure and prevention of all diseases,” Euronews reported.

Movement Triggers a Hidden ‘Brain Cleaning’ Mechanism, Study Shows

We already know that moving your body is important for brain health, but a new study reveals a possible reason why: It could be triggering a kind of hydraulic pump that flushes out fluid in the brain.

By studying mice and conducting simulations, researchers at the Pennsylvania State University (Penn State) have found that movements in the abdominal muscles can ripple all the way up to the brain, potentially cleaning out waste materials that build up during the day.

It’s tangible evidence that what goes on in our brains and our bodies isn’t so separate after all, and a good reminder to get that body moving, in whatever way works for you, throughout the day.

The Age of Biohacking: Redefining Human Potential in the 21st Century

In a world where technology and biology converge at an accelerating pace, a new era of self-improvement is emerging — biohacking. This once-niche movement has transformed into a global phenomenon, attracting everyone from Silicon Valley executives to amateur enthusiasts. The promise? To optimize the human mind and body beyond natural limits using a blend of science, lifestyle adjustments, and cutting-edge technology.

But what exactly is biohacking? Is it the future of personal health and evolution, or a slippery slope into risky experimentation? In this article, we’ll delve deep into the world of biohacking — its origins, principles, popular techniques, controversies, and future potential. Whether you’re a skeptic, a curious observer, or a self-improvement junkie, the world of biohacking has something provocative for everyone.

Brain-based index may reveal Alzheimer’s risk patterns in adults as young as 30

Over the past few decades, neuroscientists and medical researchers worldwide have been trying to leverage available health records, brain scans and other medical data to uncover biological markers associated with the onset of specific diseases or neuropsychiatric disorders. The identification of these biomarkers could help to devise new tools to predict the risk that individual patients will develop a specific condition, allowing doctors to intervene early, preventing or delaying its emergence or slowing down its progression.

Researchers at the University of Texas Health Science Center, UTHealth Houston School of Behavioral Health Sciences, Keck School of Medicine of USC, and University of Maryland School of Medicine recently devised a new brain-based index that could be used to track early risk factors that, in specific people, may lead to the development of Alzheimer’s disease (AD). AD is a progressive neurodegenerative condition that prompts the deterioration and death of brain cells, leading to progressive memory loss and a decline in mental functions. AD has very limited treatment options after the diagnosis but the brain changes that culminate in AD take decades, thus suggesting that public effort should be focused on prevention.

The researchers devised an index that could be used to quantify patterns in a person’s brain that measure the similarity to those observed in individuals diagnosed with AD and followed as a part of the research studies such as Alzheimer’s Disease Neuroimaging Initiative (ADNI). This index, introduced in a paper published in Molecular Psychiatry, was derived by performing a mega-analysis of publicly available brain imaging data collected from people with and without AD.

‘Solar-blind’ 2D heterostructure delivers 422-fold responsivity gain for UV sensing

Photodetectors remain a critical component in the development of advanced electronics and photonics, particularly in the role of signal readout through the conversion of photons into electrons. These digital imaging components are ubiquitous in sensors, cameras, adaptive displays, telecommunications, LiDAR systems, health monitoring wearables, and oximeters.

In the quest toward the next generation of optoelectronic devices, the spotlight lands upon ultrathin 2D materials with improved performance for integrated circuits and wearable electronics. In a recent study published in ACS Applied Electronic Materials, a team of researchers led by Haizhao Zhi and Eng Tuan Poh introduced a series of wide bandgap 2D materials—transition metal thio(seleno)phosphates into the light.

The team focused on manganese thiophosphate (MnPS3), a wide-bandgap semiconductor that is naturally “solar-blind,” meaning it is highly sensitive to UV light while remaining transparent to much of the visible spectrum. While MnPS3 is an excellent candidate for UV sensing, its performance as a standalone material is often limited by low carrier mobility—it acts almost like a “near-perfect insulator.”

Physical exercise protects against Toxoplasma gondii infection-induced muscle atrophy and microvascular rarefaction

FNDC5/irisin detection was performed by a sandwich ELISA reaction using DuoSet® ELISA Development Systems kit (R&D Systems), according to manufacturer’s instructions. Blood samples were collected at 10 or 40 dpi, allowed to sit for at least 1 h, and then centrifuged for 10 min at 224 g in a refrigerated centrifuge (4 °C) to isolate the serum. Samples were stored at −80 °C until irisin detection.

Serum samples were assayed for TNF-α, INF-γ, IL-2, IL-4, IL-6, IL-10, and IL-17a using a Cytometric Bead Array (CBA) Th1/ Th2/ Th17 kit (BD Biosciences), according to the manufacturer’s instructions. Data were acquired using a Cytoflex S (Beckman Coulter) flow cytometer. After data acquisition, dedicated software (FCAP Array, BD Biosciences) was used to analyze the results by gating bead populations, calculating MFI values, generating standard curves, and determining analyte concentrations. These analyses were performed at the Flow Cytometry Facility of the Instituto Oswaldo Cruz (Fiocruz).

T. gondii infection was quantified using RT-qPCR with bag1 and enolase2 primers to detect bradyzoite and tachyzoite forms, respectively, according to49. Ct values were compared to a standard curve amplification, derived from known T. gondii RNA concentrations. The standard curve was constructed with six 10-fold dilutions, starting with 6.0 × 106 parasites for either bradyzoites or tachyzoites. Primer sequences are available in Table 2.

/* */